Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon-alpha for AML Relapse Prevention Post-Transplant
NCT03121079Withdrawn
- Sponsor
- Peking University People's Hospital
- Start
- May 2017
- Primary completion
- Dec 2019
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Open-label, single-arm trial of interferon alfa-2b in acute myeloid leukemia (AML), sponsored by Peking University People's Hospital. Primary endpoint: Cumulative Incidence of Relapse at 1 year. Planned start May 2017; status: withdrawn.
02
Drugs
interferon alfa-2b
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03121079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03121079.